News | December 06, 2023
Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Advances Amgen's mission to serve patients with rare disease medicines
Dr Jitendra Singh launches API Chapter of AFMC, Pune; inaugurates the first annual conference of API-AFMS Continuing Medical Education (CME) on “Emerging trends in the practice of Medicine”
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Subscribe To Our Newsletter & Stay Updated
